Table 1.
Demographics and attitudes toward MRD in multiple myeloma.
| Question | Clinicians not assessing for MRD in myeloma clinically (n = 32) | Clinicians assessing for MRD in myeloma clinically (n = 57) | All respondents (n = 89) |
|---|---|---|---|
| Practice setting | |||
| Academic Health System | 23 (72%) | 45 (79%) | 68 (76%) |
| Private Practice/Hybrid | 9 (28%) | 12 (21%) | 21 (24%) |
| Geographic location | |||
| North America | 20 (63%) | 38 (67%) | 58 (65%) |
| Europe | 3 (9%) | 17 (30%) | 20 (23%) |
| South America | 5 (16%) | 2 (4%) | 7 (8%) |
| Australia | 2 (6%) | 0 | 2 (2%) |
| Asia | 2 (6%) | 0 | 2 (2%) |
| Africa | 0 | 0 | 0 |
| Practice Experience, median (range) | |||
| Years in practice | 10 (1–31) | 10 (1–40) | 10 (1–40) |
| Myeloma patient visits/week | 15 (1–100) | 20 (1–100) | 20 (1–100) |
| Assess for MRD on Clinical Trials | 12 (38%) | 45 (79%) | 57 (64%) |
| Reasons for not clinically assessing for MRDa | |||
| Not able to order MRD test | 7 (22%) | – | – |
| Unclear when to assess for MRD | 7 (22%) | – | – |
| Not actionable result | 6 (19%) | – | – |
| Cost/insurance coverage | 5 (16%) | – | – |
| Discomfort of bone marrow aspiration | 3 (9%) | – | – |
| Insufficient test sensitivity | 1 (3%) | – | – |
| Not an appropriate surrogate endpoint | 1 (3%) | – | – |
| Not familiar with MRD as an endpoint | 0 | – | – |
| Concerns about MRD guiding decision making in myelomaa | |||
| No data to support decision making | 14 (44%) | 36 (63%) | 50 (56%) |
| Unclear when to assess for MRD | 12 (38%) | 25 (44%) | 37 (42%) |
| Discomfort of bone marrow aspiration | 8 (25%) | 14 (25%) | 22 (25%) |
| Cost/insurance coverage | 4 (13%) | 18 (32%) | 22 (25%) |
| Not a surrogate endpoint for OS | 6 (19%) | 12 (21%) | 18 (20%) |
| Insufficient test sensitivity | 3 (9%) | 3 (5%) | 6 (7%) |
| No concerns | 3 (9%) | 3 (5%) | 6 (7%) |
aUp to 3 answers allowed.